0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Multiple Desmoplastic Melanomas in Birt-Hogg-Dubé Syndrome and a Proposed Signaling Link Between Folliculin, the mTOR Pathway, and Melanoma Susceptibility

Raymond A. Cocciolone, MBBS; Kerry A. Crotty, MBBS; Lesley Andrews, MBBS; Nikolas K. Haass, MD, PhD; Fergal J. Moloney, MD
Arch Dermatol. 2010;146(11):1316-1318. doi:10.1001/archdermatol.2010.333.
Text Size: A A A
Published online

Extract

Birt-Hogg-Dubé syndrome (BHDS) is a rare autosomal dominant disorder characterized by the development of cutaneous and systemic tumors.1 The BHD gene (OMIM 135150) codes for the protein folliculin, which is expressed in multiple tissues including kidney, lung, and skin.1 Folliculin is thought to play a role in tumor suppression exerting an inhibitory effect on the growth-promoting mammalian target of rapamycin (mTOR) pathway.2 Mutations observed within the BHD gene in BHDS lead to the expression of inactive folliculin, ultimately resulting in mTOR pathway activation.3 Unregulated mTOR activation promotes cell growth and proliferation, as observed in melanoma pathogenesis.3,4

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption
Figure 2

The putative interaction of the folliculin/FNIP1/FNIP2/AMPK complex with the mammalian target of rapamycin (mTOR) pathway in melanoma. The BHD mutation in Birt-Hogg-Dubé syndrome leads to folliculin inactivation and thus to mTOR activation and may therefore play an additional role in tumor promotion. Rapamycin and its analogs inhibit mTOR and may compensate for the inactive folliculin/FNIP1/FNIP2/AMPK complex. AKT indicates proto-oncogene serine-threonine protein kinase; AMPK, adenosine monophosphate–activated protein kinase; FNIP, folliculin interacting protein; MAPK, mitogen-activated protein kinase; mTORC1, mTOR/raptor complex; mTORC2, mTOR/rictor complex; PI3K, phosphatidylinositol 3-kinase; Rheb, GTP-binding protein Ras homolog enriched in brain; TSC1/2, tuberous sclerosis complex 1/2.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 1

Clinical and histopathologic images. A, Multiple small skin-colored papules on the nose and cheek. Note site of prior melanoma excision and grafting on right cheek. B, Photomicrograph of fibrofolliculoma exhibiting an expanded follicular structure with internal strands of epithelium surrounded by loose connective tissue with an increase in fibroblasts (hematoxylin-eosin, original magnification ×4). C, Featureless nodule on left shoulder; histologic analysis showed a desmoplastic melanoma with a Breslow thickness of 2.4 mm.

Graphic Jump Location

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

208 Views
3 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();